Harvard Bioscience Ushers in New Financial Chapter with Interim CFO Appointment

Harvard Bioscience has announced that Jennifer Cote, its Chief Financial Officer and Treasurer, will step down following the company’s next 10-Q filing, expected by May 12, 2025. Stepping into the interim CFO role is Mark Frost, a seasoned executive with over three decades of experience across private and public companies. Frost has been consulting with Harvard Bioscience since January and brings deep financial expertise from prior roles at Fathom, Argon Medical Devices, and a series of public healthcare companies, including Analogic and AngioDynamics.

Chairman and CEO Jim Green expressed confidence in Frost’s ability to steer the finance team, citing his proven track record and strategic leadership. He also extended gratitude to Cote, recognizing her contributions in driving operational improvements and leading initiatives like the company’s ERP system consolidation. As the company continues to navigate a competitive and evolving market, the leadership transition signals a commitment to financial stability and future-focused growth.